Oric Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

ORIC$8.82+3.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	September 30, 2024	December 31, 2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$44,230	$23,384
Short-term investments	228,139	184,803
Prepaid expenses and other current assets	7,059	4,410
Total current assets	279,428	212,597
Long-term investments	9,998	26,852
Property and equipment, net	3,091	2,862
Other assets	9,553	9,696
Total assets	$302,070	$252,007
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$4,249	$944
Accrued liabilities	16,999	19,514
Total current liabilities	21,248	20,458
Other long-term liabilities	6,828	7,461
Total liabilities	28,076	27,919
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 70,559,183 and 54,865,553 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	7	6
Additional paid-in capital	799,732	658,751
Accumulated deficit	(526,467)	(434,927)
Accumulated other comprehensive income	722	258
Total stockholders' equity	273,994	224,088
Total liabilities and stockholders' equity	$302,070	$252,007

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.